<div id="readability-page-1"><p>OMNI 360 Wealth Inc. lifted its stake in shares of  Merck &amp; Co., Inc. (NYSE:MRK - Free Report) by 252.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor  owned 9,457 shares of the company's stock after purchasing an additional 6,772 shares during the period. OMNI 360 Wealth Inc.'s holdings in Merck &amp; Co., Inc. were worth $749,000 at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>Merck &amp; Co., Inc.</strong> alerts:</span></p></div><ul><li>As the Market Rotates, This Healthcare ETF Is Leading the Way</li></ul><p>A number of other institutional investors and hedge funds have also modified their holdings of the business. Thurston Springer Miller Herd &amp; Titak Inc. raised its stake in shares of  Merck &amp; Co., Inc. by 24.3% during the second quarter. Thurston Springer Miller Herd &amp; Titak Inc. now owns 16,081 shares of the company's stock worth $1,273,000 after buying an additional 3,141 shares during the last quarter.  Douglas Lane &amp; Associates LLC increased its stake in  Merck &amp; Co., Inc. by 1.7% in the second quarter. Douglas Lane &amp; Associates LLC now owns 519,901 shares of the company's stock valued at $41,155,000 after purchasing an additional 8,486 shares in the last quarter.  McLean Asset Management Corp increased its position in shares of  Merck &amp; Co., Inc. by 3.7% during the second quarter. McLean Asset Management Corp now owns 3,543 shares of the company's stock worth $292,000 after acquiring an additional 125 shares in the last quarter.  Sage Capital Advisors llc bought a new stake in shares of  Merck &amp; Co., Inc. during the second quarter worth $4,042,000.  Finally, Fiduciary Financial Group LLC increased its position in shares of  Merck &amp; Co., Inc. by 7.7% during the second quarter. Fiduciary Financial Group LLC now owns 7,267 shares of the company's stock worth $595,000 after acquiring an additional 521 shares in the last quarter. 76.07% of the stock is owned by institutional investors. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several equities research analysts have recently issued reports on the stock. Morgan Stanley lowered their price objective on shares of Merck &amp; Co., Inc. from $99.00 to $98.00 and set an &#34;equal weight&#34; rating for the company in a research report on Thursday, July 10th. Wells Fargo &amp; Company reduced their target price on shares of Merck &amp; Co., Inc. from $97.00 to $90.00 and set an &#34;equal weight&#34; rating for the company in a report on Wednesday, July 30th. Finally, Cantor Fitzgerald cut shares of Merck &amp; Co., Inc. from an &#34;overweight&#34; rating to a &#34;cautious&#34; rating in a report on Tuesday, May 20th. One investment analyst  has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have given a Hold rating and one  has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and an average target price of $107.44.</p><ul><li>Moderna  Stock Looks Ripe for a Short Squeeze</li></ul><p><b>Read Our Latest Analysis on Merck &amp; Co., Inc.</b></p><h2>Merck &amp; Co., Inc. Stock Performance</h2><p>Shares of MRK stock opened at $82.87 on Friday. The stock has a market cap of $206.99 billion, a P/E ratio of 12.77, a P/E/G ratio of 0.87 and a beta of 0.37. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.42 and a quick ratio of 1.17. The company has a fifty day moving average price of $82.93 and a two-hundred day moving average price of $82.81. Merck &amp; Co., Inc. has a one year low of $73.31 and a one year high of $119.38. </p><ul><li>Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares</li></ul><p>Merck &amp; Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $2.13 EPS for the quarter, beating analysts' consensus estimates of $2.03 by $0.10. The firm had revenue of $15.81 billion during the quarter, compared to analysts' expectations of $15.92 billion. Merck &amp; Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%.  Merck &amp; Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. As a group, equities analysts predict that  Merck &amp; Co., Inc. will post 9.01 EPS for the current year. </p><h2>Merck &amp; Co., Inc. Announces Dividend</h2><p>The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 7th. Shareholders of record on Monday, September 15th will be paid a $0.81 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.24 dividend on an annualized basis and a yield of 3.9%. Merck &amp; Co., Inc.'s dividend payout ratio (DPR) is currently 49.92%. </p><h2>Merck &amp; Co., Inc. Profile</h2> (Free Report)<p>Merck &amp; Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Merck &amp; Co., Inc.</li><li>How to Use Stock Screeners to Find Stocks</li><li>Ride the Luxury Retail Wave with These 3 High-End Brand Stocks</li><li>How to Invest in Insurance Companies: A Guide </li><li>Wall Street Quietly Bets Big on These Chinese Tech Giants</li><li>3 Must-Buy Warren Buffett Stocks for Volatile Times</li><li>Meta's $600B U.S. Investment: Bearish or Bullish for Shares? </li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1SSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1SSw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Merck &amp; Co., Inc. Right Now?</h2><p>Before you consider Merck &amp; Co., Inc., you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck &amp; Co., Inc. wasn't on the list.</p><p>While Merck &amp; Co., Inc. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>OMNI 360 Wealth Inc. increased its stake in Merck & Co., Inc. by 252.2% in Q2, owning 9,457 shares valued at $749,000. Other institutional investors also raised their stakes. Analysts have mixed ratings on Merck, with a consensus rating of "Hold" and an average target price of $107.44. Merck's stock opened at $82.87, with a market cap of $206.99 billion. The company reported $2.13 EPS for the last quarter, exceeding estimates, and declared a quarterly dividend of $0.81 to be paid on October 7th.</p>

OMNI 360 Wealth Inc. Has $749,000 Stake in Merck & Co., Inc. $MRK